PURE Bioscience, Inc.
PURE · OTC
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.17 | 0.25 | -0.10 |
| FCF Yield | -20,059.16% | -28.35% | -34.97% | -14.28% |
| EV / EBITDA | -2,341.30 | -3.78 | -2.45 | -4.31 |
| Quality | ||||
| ROIC | -1,893.33% | -3,683.53% | -304.95% | -87.62% |
| Gross Margin | 59.17% | 58.69% | 51.73% | 53.97% |
| Cash Conversion Ratio | 0.84 | 0.76 | 0.83 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 954.67% | 1.94% | -21.81% | -35.54% |
| Free Cash Flow Growth | -79,512.80% | 23.56% | -32.49% | -48.05% |
| Safety | ||||
| Net Debt / EBITDA | -2,336.51 | -0.85 | 0.02 | 1.04 |
| Interest Coverage | -7.60 | -20.20 | -281.64 | -570.83 |
| Efficiency | ||||
| Inventory Turnover | 6.38 | 14.48 | 10.30 | 4.77 |
| Cash Conversion Cycle | -182.49 | -189.87 | -79.14 | -92.63 |